June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Mouse Studies Support Intravitreal Gene Therapy for Blue Cone Monochromacy
Author Affiliations & Notes
  • Ruslan Grishanin
    Adverum Biotechnologies, Menlo Park, California, United States
  • Diana Cepeda
    Adverum Biotechnologies, Menlo Park, California, United States
  • James Ver Hoeve
    OSOD, Madison, Wisconsin, United States
  • Christine Dowd
    Adverum Biotechnologies, Menlo Park, California, United States
  • Kristina Bender
    Adverum Biotechnologies, Menlo Park, California, United States
  • Kelly Hanna
    Adverum Biotechnologies, Menlo Park, California, United States
  • Julio Nieves
    Adverum Biotechnologies, Menlo Park, California, United States
  • Edward Yeh
    Adverum Biotechnologies, Menlo Park, California, United States
  • Pallavi Sharma
    Adverum Biotechnologies, Menlo Park, California, United States
  • Claire Gelfman
    Adverum Biotechnologies, Menlo Park, California, United States
  • Mehdi Gasmi
    Adverum Biotechnologies, Menlo Park, California, United States
  • Footnotes
    Commercial Relationships   Ruslan Grishanin, Adverum (E); Diana Cepeda, Adverum (E); James Ver Hoeve, Adverum (C); Christine Dowd, Adverum (E); Kristina Bender, Adverum (E); Kelly Hanna, Adverum (E); Julio Nieves, Adverum (E); Edward Yeh, Adverum (E); Pallavi Sharma, Adverum (E); Claire Gelfman, Adverum (E); Mehdi Gasmi, Adverum (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4499. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ruslan Grishanin, Diana Cepeda, James Ver Hoeve, Christine Dowd, Kristina Bender, Kelly Hanna, Julio Nieves, Edward Yeh, Pallavi Sharma, Claire Gelfman, Mehdi Gasmi; Mouse Studies Support Intravitreal Gene Therapy for Blue Cone Monochromacy. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4499.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subfoveal injection of recombinant adeno-associated virus (AAV)-based gene therapy to restore opsin expression in foveal cones poses a risk to the fragile central retinal structure in blue cone monochromacy (BCM), a rare X-linked retinal disease resulting from the congenital absence of L- and M- opsins. Although many (non-functional) cones are present in retina of patients with BCM, varying degrees of macular thinning present a challenge for subretinal delivery. We are developing ADVM-062 (AAV2.7m8-MNTC-hOPN1LW), an AAV vector for cone-specific expression of human L-opsin (hLopsin) and optimized for intravitreal (IVT) delivery. Pharmacological activity of this IVT injected vector was tested in wt C57BL/6 mice that naturally lack L-opsin.

Methods : Animals received a single IVT injection of ADVM-062 or vehicle; the contralateral eye served as a control. To isolate hLopsin-mediated function, ERG responses to 660 nm flashes of fixed intensity were measured in the presence of a ganzfeld background of 513 nm and varying intensities.
In addition, cone-isolating 25 Hz flicker ERG responses to 660 nm flashes were recorded. ERGs were recorded 3, 6 and 11 weeks post-dose. ERG amplitude measures from treated and control eyes were compared using 2 way ANOVA followed by post-hoc Sidak’s test. Anatomic localization of hLopsin expression was evaluated by immunofluorescence using an ADVM-062 surrogate engineered to express hLopsin with a myc-tag.

Results : Compared with naïve and vehicle controls, a single IVT dose of ADVM-062 resulted in significantly augmented ERG responses to long-wavelength stimuli presented on the desensitizing backgrounds (p<0.01). The augmented long-wavelength ERG response was evident as early as 3 weeks post-dose. Increased 25 Hz flicker ERG responses to 660 nm light confirm the cone-specific nature of this sensitization. Immunofluorescence demonstrated that hLopsin expression was localized exclusively to cone photoreceptor cells.

Conclusions : A single IVT dose of ADVM-062 expressing hLopsin effectively transduces murine cone photoreceptors and produces a de novo response to long wavelength stimuli. Expression occurred 3 weeks after injection and lasted for at least 11 weeks. Our previous studies in gerbils show that the IVT-augmented long wavelength ERG is sustained for at least 1 year. Findings support further evaluation of ADVM-062 as a potential IVT-delivered treatment for BCM patients.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×